Full Press Release Details
Cutting-Edge Progress Meets Pragmatism
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
FDMT Neutral Sentiment
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Key Takeaway: The article discusses the future of biopharma, specifically focusing on research and development innovation expected in 2026. It highlights the intersection of cutting-edge progress and practical considerations in the industry. The content is part of a series that examines various aspects of biopharma's evolution.
Price reaction · baseline $9.515 (2026-04-01T14:05:00.000Z) · hit during market hours · clean, no other FDMT news in the window
day 0 close · peak
+3.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration